Scholarlink

Background <p>Lupeol acetate, a naturally occurring pentacyclic triterpenoid with anti-inflammatory, antioxidant, and cardioprotective properties, was identified from the methanolic extract of <i>Cleome viscosa</i> leaves as a promising therapeutic candidate for myocardial infarction (MI), based on its favorable pharmacokinetic and safety profile.</p> Methods <p>The methanolic extract of&#xa0;<i>Cleome viscosa</i>&#xa0;was analyzed using gas chromatography-mass spectrometry (GC–MS) to identify bioactive compounds. Pharmacokinetics, drug-likeness, and toxicity were assessed using SwissADME, MolSoft, and ProTox-II tools. Differentially expressed genes (DEGs) from MI datasets were integrated with small-molecule targets through Protein–protein interaction (PPI) networks were construction followed by weighted gene co-expression network analysis (WGCNA) to identify key hub genes. Molecular dynamics simulations validated the stability of the interactions between lupeol acetate and target proteins.</p> Results <p>Among 32 identified compounds, lupeol acetate exhibited favorable pharmacokinetics, low toxicity, and high drug-likeness. WGCNA revealed JAK2, a key regulator of inflammatory pathways and immune signaling, as a critical hub gene associated with MI-related mechanisms, including apoptosis and inflammation. Molecular docking demonstrated strong binding between lupeol acetate and JAK2, which was confirmed by molecular dynamics simulations showing a stable protein–ligand complex.</p> Conclusion <p>This study identifies lupeol acetate as a promising cardioprotective candidate. By integrating WGCNA with computational analyses, it provides novel insights into the molecular mechanisms of <i>Cleome viscosa</i>. These findings support further in vivo validation and development of lupeol acetate for therapeutic use in myocardial infarction.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lupeol acetate from Cleome viscosa as a therapeutic candidate for myocardial infarction

  • 期刊论文

  • 发表日期：

    2025年7月3日

查看全文
  • James Diokadan,
  • Ishimwe Aimée Divine,
  • Shamasamu Emma,
  • Rutendo Samantha Makiwa,
  • Uwizera Celine,
  • Lucky Nicholus,
  • Ssekikubo Ronald,
  • Sreya Kosanam,
  • Rajeshwari Pasupula

摘要

Background

Lupeol acetate, a naturally occurring pentacyclic triterpenoid with anti-inflammatory, antioxidant, and cardioprotective properties, was identified from the methanolic extract of Cleome viscosa leaves as a promising therapeutic candidate for myocardial infarction (MI), based on its favorable pharmacokinetic and safety profile.

Methods

The methanolic extract of Cleome viscosa was analyzed using gas chromatography-mass spectrometry (GC–MS) to identify bioactive compounds. Pharmacokinetics, drug-likeness, and toxicity were assessed using SwissADME, MolSoft, and ProTox-II tools. Differentially expressed genes (DEGs) from MI datasets were integrated with small-molecule targets through Protein–protein interaction (PPI) networks were construction followed by weighted gene co-expression network analysis (WGCNA) to identify key hub genes. Molecular dynamics simulations validated the stability of the interactions between lupeol acetate and target proteins.

Results

Among 32 identified compounds, lupeol acetate exhibited favorable pharmacokinetics, low toxicity, and high drug-likeness. WGCNA revealed JAK2, a key regulator of inflammatory pathways and immune signaling, as a critical hub gene associated with MI-related mechanisms, including apoptosis and inflammation. Molecular docking demonstrated strong binding between lupeol acetate and JAK2, which was confirmed by molecular dynamics simulations showing a stable protein–ligand complex.

Conclusion

This study identifies lupeol acetate as a promising cardioprotective candidate. By integrating WGCNA with computational analyses, it provides novel insights into the molecular mechanisms of Cleome viscosa. These findings support further in vivo validation and development of lupeol acetate for therapeutic use in myocardial infarction.